Anti-interleukin-6 Receptor Antibody (Tocilizumab) Treatment of Multicentric Castleman's Disease

Abstract

We report three cases of multicentric Castleman's disease (MCD)

Inflammation and the Silent Sequelae of Stroke

“…And, as with depression, the administration of proinflammatory cytokines [e.g., interleukin (IL)-6] is associated with the perception of fatigue [49]. Further, treatment with cytokine antagonists is associated with a decrease in fatigue-administration of exogenous IL-1ra (anakinra) decreases fatigue in patients with Sjögren's syndrome [50], and the tumor necrosis factor (TNF)-α receptor antagonist infliximab and the IL-6 receptor antagonist toclizumab reduce fatigue in patients with cancer and autoimmune diseases [51][52][53][54][55].…”

“…Treatment with exogenous IL-1ra (anakinra), for instance, decreases fatigue in patients with Sjögren's syndrome [50]. Similarly, the TNF-α receptor antagonist infliximab and the IL-6 receptor antagonist tocilizumab reduce fatigue in patients with cancer [51] and a variety of autoimmune diseases [52][53][54][55]. Fatigue is a particularly prevalent problem for patients with multiple sclerosis (MS) [117].…”

Targeting Interleukin-6 in Rheumatoid Arthritis

“…In Japan, it is also licensed for use in the treatment of Castleman's disease [29]. There are also case reports in regards to the use of tocilizumab in other auto-immune conditions such as giant cell arteritis [30,31], adult onset Still's disease [32] , systemic lupus erythematosus [33], ANCA-associated vasculitis [34], Behcet's disease [35,36], systemic sclerosis [37] and polymyositis [38].…”

Selective killing of Kaposi's sarcoma-associated herpesvirus lytically infected cells with a recombinant immunotoxin targeting the viral gpK8.1A envelope glycoprotein

“…16,24,25 Antineoplastic chemotherapy with single or combination agents has yielded clinical remissions, though the responses are typically transient and drug toxicities limit extended use. Successes have been reported with immunotherapy using monoclonal antibodies (mAbs) tocilizumab (Actemra ® ), 26 and siltuximab 27 against interlekin-6 or rituximab against the B-cell antigen CD20, 18,[28][29][30][31] though the latter agent has been complicated by aggravation of KS lesions. 28,29,32 A recent report described MCD remission in a multiple myeloma patient undergoing treatment with the proteosome inhibitor bortezomib.…”